Home
About
Capabilities
R&D
Investors
News
Careers
简
繁
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
Jun 05, 2026
Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
➞
Jun 04, 2026
Mabwell’s Subsidiary Myvision Appears at Retina China 2026
➞
Jun 03, 2026
Highlights in Oral Presentation of Mabwell's 9MW2821 at 2026 ASCO
➞
Jun 02, 2026
Press Conference on Early Diagnosis and Clinical Translation of Parkinson’s Disease & SST001 Clinical Trial Initiation Meeting Successfully Held
➞
May 29, 2026
Mabwell Announces First Patient Dosing in Phase III Study of Bulumtatug Fuvedotin in TNBC Patients
➞
May 22, 2026
Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
➞
May 21, 2026
Mabwell Announces NMPA Approval of Supplemental Application for Additional Indications of MAIWEIJIAN (Denosumab Injection)
➞
May 12, 2026
Mabwell to Present Two Clinical Study Results as Oral Presentation at Retina China 2026
➞
May 08, 2026
Mabwell’s 9MW5211 Receives FDA Clearance for Clinical Trial Application
➞
Apr 30, 2026
2026 WOC | Mabwell to Present Latest Clinical Data on 9MW0211 for nAMD in Poster Presentations
➞
1
2
3
Next